compani
latest consensu
today rais po
ahead lilli report result tomorrow market open
assess latest consensu estim today reiter
buy rate increas probability-weight npv base po
go call see better anticip result
current captur consensu view lilli growth profil
defens continu differenti well earn season
mil
mil
mil
con past week
past week
con past week
con past week
top question call
anticip top five question go call give
confid maintain guidanc despit covid crisi
expect impact fda review selpercatinib approv
suspend clinic trial impact data readout tirzepatid mirikizumab earli
oncolog diabet franchis go lower-pr
plan addit bolt-on throughout
lilli host call tomorrow et dial passcod
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
compani
price object base probability-adjust net present valu npv
analysi franchis vertic includ endocrinolog oncolog
pharmaceut product earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product depend stage develop appli
termin valu rang cardiolog pipelin base project sale
declin follow loss exclus within busi vertic
risk price object better expect launch compet
product emerg clinic data pipelin asset confirm prior
observ failur effect commerci approv product potenti
drug price system restructur us
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani april
